SGEN - Why Is Seagen Stock Trading Higher Today? | Benzinga
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase 3 EV-302 trial for Padcev (enfortumab vedotin-ejfv) combined with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) versus chemotherapy in bladder cancer.
The trial included patients with previously untreated locally advanced or metastatic urothelial cancer, a ...